These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33611869)

  • 41. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
    Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
    Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis.
    Kelly A; Tymms K; Tunnicliffe DJ; Sumpton D; Perera C; Fallon K; Craig JC; Abhayaratna W; Tong A
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):525-532. PubMed ID: 28732151
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COVID-19 and rheumatoid arthritis.
    D'Silva KM; Wallace ZS
    Curr Opin Rheumatol; 2021 May; 33(3):255-261. PubMed ID: 33625043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Two-year adherence and costs for biologic therapy for rheumatoid arthritis.
    Stolshek BS; Wade S; Mutebi A; De AP; Wade RL; Yeaw J
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP315-SP321. PubMed ID: 30020744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Cross-sectional Survey on the Preference of Patients with Rheumatoid Arthritis for Route of Administration of Disease-Modifying Anti-Rheumatic Drugs: Oral Target-Specific Versus Parenteral Biologic.
    Edel Y; Sagy I; Pokroy-Shapira E; Oren S; Dortort Lazar A; Egbaria M; Shiber S; Tal BS; Molad Y
    Isr Med Assoc J; 2020 Mar; 22(3):154-159. PubMed ID: 32147979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: Results from prospective nationwide KOBIO Registry.
    Kim SK; Kwak SG; Choe JY
    Medicine (Baltimore); 2020 Feb; 99(9):e19415. PubMed ID: 32118795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment.
    Alivernini S; Mazzotta D; Zoli A; Ferraccioli G
    Drugs Aging; 2009; 26(5):395-402. PubMed ID: 19552491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
    Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
    Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
    Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy.
    Ingegnoli F; Cincinelli G; Luppino AF; Favalli EG; Orenti A; Boracchi P; Caporali R
    Ann Rheum Dis; 2021 Sep; 80(9):1243-1245. PubMed ID: 33849919
    [No Abstract]   [Full Text] [Related]  

  • 52. Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: A subgroup analysis of Japanese patients from a large international cohort study (SENSE).
    Kawahito Y; Takakubo Y; Morinobu A; Matsubara N; Nagy O; Sugiyama E
    PLoS One; 2021; 16(11):e0259389. PubMed ID: 34780502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Ishikawa Y; Hashimoto M; Ito H; Tanaka M; Yukawa N; Fujii T; Yamamoto W; Mimori T; Terao C
    Semin Arthritis Rheum; 2019 Oct; 49(2):204-210. PubMed ID: 30803720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
    Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
    PLoS One; 2019; 14(5):e0216624. PubMed ID: 31067271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Managing rheumatoid arthritis during COVID-19.
    Roongta R; Ghosh A
    Clin Rheumatol; 2020 Nov; 39(11):3237-3244. PubMed ID: 32892311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice.
    Kaufmann J; Feist E; Roske AE; Schmidt WA
    Clin Rheumatol; 2013 Sep; 32(9):1347-55. PubMed ID: 23703358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.
    Sparks JA; Lesperance T; Accortt NA; Solomon DH
    Arthritis Care Res (Hoboken); 2019 Apr; 71(4):512-520. PubMed ID: 29799667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020.
    Norris-Grey C; Cambridge G; Moore S; Reddy V; Leandro M
    Rheumatology (Oxford); 2022 Feb; 61(2):591-596. PubMed ID: 33769451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis.
    Hasegawa E; Ito S; Kurosawa Y; Kobayashi D; Otani H; Abe A; Nakazono K; Murasawa A; Narita I; Ishikawa H
    Intern Med; 2023; 62(3):373-379. PubMed ID: 36725065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis?
    Hasseli R; Pfeil A; Hoyer BF; Krause A; Lorenz HM; Richter JG; Schmeiser T; Voll RE; Schulze-Koops H; Specker C; Müller-Ladner U
    Clin Exp Rheumatol; 2021; 39(3):639-647. PubMed ID: 33822706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.